MENU

VSTM Verastem Forecast, Technical & Fundamental Analysis

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer... Show more

Industry: #Biotechnology
A.I.Advisor
Nov 14, 2026

Verastem Oncology (VSTM) Stock Forecast: KRAS Pipeline and Data Readouts Set the Stage

Key Takeaways

  • Commercial inflection underway: The AVMAPKI FAKZYNJA CO-PACK launch in recurrent low-grade serous ovarian cancer is scaling rapidly, with revenue growth outpacing consensus and providing a revenue base that supports pipeline investment.
  • VS-7375 is the central forward catalyst: The oral KRAS G12D inhibitor is advancing through registrational studies across pancreatic, colorectal, and lung cancers, with initial data readouts and Phase 3 starts expected to drive sentiment.
  • Confirmatory trial defines durability: The RAMP 301 Phase 3 readout, expected around mid-2027, is a pivotal event that could convert the accelerated approval into traditional approval and broaden the label.
  • Crowded but expanding field: Verastem competes against larger, well-capitalized rivals in the KRAS space, making differentiation on tolerability and efficacy a decisive strategic factor.
  • Capital and dilution risk remain relevant: With a cash runway extending into the second half of 2027, future financing decisions could shape both the cost structure and the shareholder base.
  • Analyst stance is constructive but evolving: Several firms have maintained Buy or Outperform ratings and raised price targets, though target revisions have been mixed as competitive dynamics shift.
  • For more detail on Verastem's Major News, Today's Price Move, Price Targets, and Earnings, explore our dedicated pages for a complete, data-driven picture.
  • For broader, algorithm-driven market ideas across many tickers, consider exploring Trending AI Robots.

Strategic Positioning and Competitive Outlook

Verastem Oncology is a commercial-stage biopharmaceutical company focused on cancers driven by the RAS/MAPK pathway — a core cellular signaling network that promotes cancer cell growth and survival. The company's near-term franchise is AVMAPKI FAKZYNJA CO-PACK, a combination of avutometinib (a RAF/MEK clamp) and defactinib (a FAK inhibitor) that received accelerated approval in May 2025 as the first therapy specifically indicated for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC).

Over the medium term, Verastem's strategic center of gravity is shifting toward VS-7375, an oral, potentially best-in-class KRAS G12D inhibitor. KRAS is one of the most frequently mutated cancer genes, and the G12D variant represents a large, largely unserved addressable market across pancreatic ductal adenocarcinoma (PDAC), colorectal cancer, and non-small cell lung cancer (NSCLC). Verastem's differentiated thesis rests on a dual ON/OFF binding mechanism, deep responses, and a tolerability profile with comparatively low gastrointestinal and liver toxicity — attributes that could distinguish it from pan-RAS rivals such as Revolution Medicines' daraxonrasib.

The structural challenge is competition and scale. The KRAS field includes Amgen, Bristol Myers Squibb, Incyte, and Revolution Medicines, several of which possess larger balance sheets. Verastem's ability to sustain a first-mover position in KRAS G12D will depend on the pace and quality of its registrational data, not on historical stock performance.

Major Catalysts Ahead

Several discrete events could materially reshape investor sentiment. The most immediate is the initial registrational data for VS-7375 across the three tumor types, which management indicated could arrive around October 2026, alongside the commencement of Phase 3 trials in the second half of 2026. Because these readouts could support an accelerated approval pathway — potentially making VS-7375 among the first approved KRAS G12D inhibitors — they carry outsized weight.

A second catalyst is the FDA decision on the AVMAPKI FAKZYNJA CO-PACK Blister Pack NDA (New Drug Application), expected by February 7, 2027. A separate confirmatory milestone is the RAMP 301 Phase 3 topline readout anticipated around mid-2027, which could validate the broader LGSOC opportunity regardless of KRAS mutation status and support label expansion in Europe and Japan.

Analyst activity has been notably constructive. Jefferies raised its price target to $13 from $11 while keeping a Buy rating, describing VS-7375 as having best-in-class potential. Mizuho maintained its rating and raised its target to $14, while RBC Capital reiterated Outperform and lifted its target to $19, and BTIG has carried an even higher target. The consensus price target sits near $15, well above recent trading levels — though individual firm targets range widely, reflecting genuine uncertainty about trial outcomes.

Industry and Macroeconomic Forces

Verastem's trajectory is sensitive to the broader biotechnology financing cycle. Unprofitable, development-stage companies are disproportionately exposed to interest-rate policy: higher rates raise the cost of capital and compress valuations, while easing conditions tend to improve access to funding and support risk appetite. The company's $136 million cash position, which extends runway into the second half of 2027, provides a buffer but also means future dilution is a live consideration.

Regulatory climate is a second macro driver. Verastem's own filings note uncertainty around U.S. healthcare policy and regulatory actions. Drug-pricing reforms, accelerated-approval scrutiny, and reimbursement changes could affect both the commercial ramp and the path to conversion of accelerated approvals. On the demand side, oncology remains structurally defensive: cancer treatment volumes are less cyclical than consumer spending, and rare-cancer niches such as LGSOC carry limited pricing competition in the near term. Geopolitical and manufacturing risks also warrant attention, given Verastem's reliance on a Chinese partner (GenFleet) for VS-7375 and third-party contract manufacturers.

Trend Prediction Engine

Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, ETF, or other asset may trend bullish, bearish, or sideways over the coming week or month. It is built to surface developing trends, evaluate potential breakouts or reversals, and let users explore predictions across a broad universe of tradable instruments. The platform organizes searchable prediction categories, incorporates historical context, and supports alert-oriented functionality to keep users informed of shifting signals. For investors tracking biotechnology names such as Verastem, tools like this can complement fundamental research by adding a quantitative, momentum-aware perspective to the decision-making process.

2026 Outlook and Long-Term Themes to Watch

Looking toward 2026 and beyond, Verastem's long-term narrative hinges on three structural themes. First is market expansion: converting the LGSOC accelerated approval into traditional approval and extending the label into Europe and Japan would enlarge the commercial opportunity for the core franchise. Second is pipeline diversification: successful VS-7375 data across pancreatic, colorectal, and lung cancers would reposition the company from a single-indication commercial player into a multi-franchise oncology platform. Third is cost and margin evolution: as revenue scales against a rising research-and-development budget, the path to profitability depends on disciplined spending and the avoidance of dilutive financing ahead of major data inflections.

Competitive threats remain the key counterweight. The pace of rival KRAS G12D programs, evolving standard-of-care regimens in pancreatic cancer, and potential regulatory delays could all compress the window of differentiation. Analyst expectations, reflected in the rising consensus price target and maintained Buy and Outperform ratings, suggest the Street is pricing in meaningful pipeline optionality — but the dispersion across targets underscores that the 2026–2027 data readouts, rather than any single forecast, will ultimately determine whether that optimism is justified.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Interact to see
Advertisement
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published Earnings

VSTM is expected to report earnings to fall 44.74% to -40 cents per share on March 18

Verastem VSTM Stock Earnings Reports
Q4'26
Est.
$-0.41
Q3'26
Missed
by $0.30
Q2'26
Beat
by $0.12
Q1'26
Beat
by $0.06
Q4'25
Beat
by $0.41
The last earnings report on November 05 showed earnings per share of -74 cents, missing the estimate of -43 cents. With 2.13M shares outstanding, the current market capitalization sits at 761.64M.
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TR37.53N/A
N/A
Tootsie Roll Industries Inc
WEAV7.40N/A
N/A
Weave Communications
TLN332.92-22.99
-6.46%
Talen Energy Corp
GCTS1.00-0.12
-10.71%
GCT Semiconductor Holding
GDC1.08-0.17
-13.60%
GD Culture Group Limited

VSTM and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, VSTM has been loosely correlated with ZYME. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if VSTM jumps, then ZYME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VSTM
1D Price
Change %
VSTM100%
-7.73%
ZYME - VSTM
44%
Loosely correlated
-2.68%
SRPT - VSTM
40%
Loosely correlated
-5.93%
MLYS - VSTM
40%
Loosely correlated
-3.53%
ARVN - VSTM
40%
Loosely correlated
-4.15%
TSHA - VSTM
39%
Loosely correlated
-1.33%
More
A.I. Advisor
published General Information

General Information

a company that discovers and develops drugs

Industry Biotechnology

Industry
Biotechnology
Address
117 Kendrick Street
Phone
+1 781 292-4200
Employees
104
Web
https://www.verastem.com
Verastem Oncology (VSTM) Stock Forecast: KRAS Pipeline and Data Readouts Set the Stage